Lataa...
STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well...
Tallennettuna:
| Julkaisussa: | Indian J Urol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Medknow Publications & Media Pvt Ltd
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6034411/ https://ncbi.nlm.nih.gov/pubmed/30034127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/iju.IJU_378_17 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|